9152 A population pharmacokinetic analysis for BIBF 1120, an angiokinase inhibitor, in patients with advanced non-small cell lung cancer

P.Stopfer; M.Freiwald; K.H.Liesenfeld; R.Bruno; L.Hodge; C.Eschbach; M.Reck; J.von Pawel; R.Kaiser; A.Staab

首页> 外文期刊>European Journal of Cancer Supplements >9152 A population pharmacokinetic analysis for BIBF 1120, an angiokinase inhibitor, in patients with advanced non-small cell lung cancer

【24h】

9152 A population pharmacokinetic analysis for BIBF 1120, an angiokinase inhibitor, in patients with advanced non-small cell lung cancer

机译：9152晚期非小细胞肺癌患者血管激酶抑制剂BIBF 1120的群体药代动力学分析

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2009年第2期|共1页
作者
P.Stopfer; M.Freiwald; K.H.Liesenfeld; R.Bruno; L.Hodge; C.Eschbach; M.Reck; J.von Pawel; R.Kaiser; A.Staab;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 9152 A population pharmacokinetic analysis for BIBF 1120, an angiokinase inhibitor, in patients with advanced non-small cell lung cancer [J] . P.Stopfer, M.Freiwald, K.H.Liesenfeld, European Journal of Cancer Supplements . 2009,第2期

机译：9152晚期非小细胞肺癌患者血管激酶抑制剂BIBF 1120的群体药代动力学分析
2. BIBF 1120intedanib: A new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer [J] . RolfoC., RaezL.E., BronteG., Expert opinion on investigational drugs . 2013,第8期

机译：BIBF 1120 / nintedanib：一种针对非小细胞肺癌患者的新型三联血管激酶抑制剂定向疗法
3. Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non-Small Cell Lung Cancer Patients [J] . Peter M. Ellis, Rolf Kaiser, Yihua Zhao, Clinical cancer research: an official journal of the American Association for Cancer Research . 2010,第10期

机译：I期开放标签研究持续治疗经预处理的非小细胞肺癌患者使用BIBF 1120，三联血管激酶抑制剂和培美曲塞进行持续治疗
4. Gene expression profiles predict survival of patients with advanced non-small cell lung cancers [C] . Harun Roslan, Hadi Jalal, Mhazir Nur Shukriyah, 2011 Fourth International Conference on Modeling, Simulation and Applied Optimization . 2011

机译：基因表达谱预测晚期非小细胞肺癌患者的生存
5. Symptoms Leading to Nutritional Risk in Advanced Non-Small Cell Lung Cancer Patients: The Importance of Nutritional Screening in the Advanced Lung Cancer Population [D] . Swinton, Nelda. 2009

机译：导致晚期非小细胞肺癌患者营养风险的症状：在晚期肺癌人群中进行营养筛查的重要性
6. A phase I open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer [O] . R. C. Doebele, P. Conkling, A. M. Traynor, -1

机译：晚期非小细胞肺癌患者以BIBF 1120联合紫杉醇和卡铂作为一线治疗连续治疗的一期开放标签剂量递增研究
7. B1-03: Phase II double blind study to investigate efficacy and safety of the triple angiokinase inhibitor BIBF 1120 in patients suffering from relapsed advanced non-small cell lung cancer (NSCLC) [O] . Reck Martin, Kaiser Rolf, Eschbach Corinna, 2007

机译：B1-03：II期双盲研究旨在研究三联血管激酶抑制剂BIBF 1120在复发性晚期非小细胞肺癌（NSCLC）患者中的疗效和安全性

9152 A population pharmacokinetic analysis for BIBF 1120, an angiokinase inhibitor, in patients with advanced non-small cell lung cancer

著录项

相似文献

相关主题

期刊订阅